Mar. 18, 2025 — A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was ...

Scaffold technology market is driven by advancements in regenerative medicine, 3D cellular models, and construction ...

"It’s been 20 years since a new medicine was approved for patients with relapsed or refractory T-ALL/LBL, which remain challenging hematologic malignancies with limited treatment options in the ...

As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.

The 21st century pharmaceutical and biotech sector has come a long way from its roots in 19th century pharmacy. pharmaphorum looks at its evolution over the centuries. The roots of the ...

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United ...

Our art critic goes room-by-room through New York’s Gilded Age house museum, reopening after nearly five years. Don’t miss the new upstairs galleries. By Holland Cotter The darkly comic ...

Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors for GLP-1, GIP and glucagon from United Biotechnology Co. Ltd. China-based ...

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with ...

Alnylam jumps as expanded US approval for heart disease drug fuels growth prospects Alnylam Pharmaceuticals' shares rose more than 10% on Friday after the drugmaker secured U.S. approval for its ...

US turns to Brazil for eggs and considers other sources during bird flu outbreak The U.S. has almost doubled imports of Brazilian eggs once used only for pet food and is considering relaxing ...

IPC Indice de Precios Y Cotizaciones 52,672.42-428.41-0.81% ...